FRAXA Research Foundation   Report issue

Foundation Phase 2
Founded: Newburyport MA United States (1994)

Organization Overview

First Clinical Trial
2002
NCT00054730
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

FRAXA Research Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autistic Disorder (Phase 2)

Fragile X Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4